BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kim YJ, Kim JW, Lee CK, Park HJ, Shim JJ, Jang JY, Dong SH, Kim HJ, Kim BH, Chang YW. [Clinical outcome of treatment with infliximab in Crohn's disease: a single-center experience]. Korean J Gastroenterol 2013;61:270-8. [PMID: 23756669 DOI: 10.4166/kjg.2013.61.5.270] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Lee JW, Choi CH, Park JH, Kim JW, Kang SB, Koo JS, Kim YH, Kim YS, Joo YE, Chang SK. Clinical features of active tuberculosis that developed during anti-tumor necrosis factor therapy in patients with inflammatory bowel disease. Intest Res 2016;14:146-51. [PMID: 27175115 DOI: 10.5217/ir.2016.14.2.146] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
2 Choi CH, Song ID, Kim YH, Koo JS, Kim YS, Kim JS, Kim N, Kim ES, Kim JH, Kim JW, Kim TO, Kim HS, Kim HJ, Park YS, Park DI, Park SJ, Song HJ, Shin SJ, Yang SK, Ye BD, Lee KM, Lee BI, Lee SY, Lee CK, Im JP, Jang BI, Jeon TJ, Cho YK, Chang SK, Jeon SR, Jung SA, Jeen YT, Cha JM, Han DS, Kim WH; IBD Study Group of the Korean Association for the Study of the Intestinal Diseases. Efficacy and Safety of Infliximab Therapy and Predictors of Response in Korean Patients with Crohn's Disease: A Nationwide, Multicenter Study. Yonsei Med J. 2016;57:1376-1385. [PMID: 27593865 DOI: 10.3349/ymj.2016.57.6.1376] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
3 Jung YS, Park DI, Kim YH, Lee JH, Seo PJ, Cheon JH, Kang HW, Kim JW. Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study. J Gastroenterol Hepatol. 2015;30:1705-1712. [PMID: 25974251 DOI: 10.1111/jgh.12997] [Cited by in Crossref: 112] [Cited by in F6Publishing: 98] [Article Influence: 18.7] [Reference Citation Analysis]
4 Shim TS. Diagnosis and Treatment of Latent Tuberculosis Infection in Patients with Inflammatory Bowel Diseases due to Initiation of Anti-Tumor Necrosis Factor Therapy. Intest Res 2014;12:12-9. [PMID: 25349559 DOI: 10.5217/ir.2014.12.1.12] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
5 Chen LK, Arai H, Chen LY, Chou MY, Djauzi S, Dong B, Kojima T, Kwon KT, Leong HN, Leung EM, Liang CK, Liu X, Mathai D, Pan JY, Peng LN, Poblete ER, Poi PJ, Reid S, Tantawichien T, Won CW. Looking back to move forward: a twenty-year audit of herpes zoster in Asia-Pacific. BMC Infect Dis 2017;17:213. [PMID: 28298208 DOI: 10.1186/s12879-017-2198-y] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 4.4] [Reference Citation Analysis]
6 Lee KM, Lee JM. Crohn's disease in Korea: past, present, and future. Korean J Intern Med 2014;29:558-70. [PMID: 25228829 DOI: 10.3904/kjim.2014.29.5.558] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]